Axon Enterprise, Inc $AXON Stock: Calamos Wealth Management LLC Grows Stake

Calamos Wealth Management LLC increased its holdings in Axon Enterprise, Inc (NASDAQ:AXON) by 1,150.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,009 shares of the biotechnology company’s stock after buying an additional 12,889 shares during the quarter. Calamos Wealth Management LLC’s holdings in Axon Enterprise were worth $5,919,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the business. State Street Corp boosted its stake in shares of Axon Enterprise by 5,700.2% during the 2nd quarter. State Street Corp now owns 213,561,844 shares of the biotechnology company’s stock worth $119,724,905,000 after acquiring an additional 209,879,882 shares during the last quarter. Envestnet Asset Management Inc. increased its stake in shares of Axon Enterprise by 18,050.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 13,200,075 shares of the biotechnology company’s stock worth $7,400,094,000 after purchasing an additional 13,127,348 shares in the last quarter. BlackRock Inc. raised its holdings in Axon Enterprise by 4.3% in the 2nd quarter. BlackRock Inc. now owns 8,334,551 shares of the biotechnology company’s stock worth $4,672,432,000 after purchasing an additional 345,365 shares during the period. Robeco Institutional Asset Management B.V. raised its holdings in Axon Enterprise by 391,214.9% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 6,988,884 shares of the biotechnology company’s stock worth $2,952,943,000 after purchasing an additional 6,987,098 shares during the period. Finally, The Manufacturers Life Insurance Company raised its holdings in Axon Enterprise by 8,432.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,537,957 shares of the biotechnology company’s stock worth $1,983,414,000 after purchasing an additional 3,496,493 shares during the period. 79.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Citigroup reissued a “market outperform” rating on shares of Axon Enterprise in a report on Monday, November 2nd. UBS Group raised their price objective on Axon Enterprise from $440.00 to $600.00 and gave the stock a “neutral” rating in a research note on Thursday, August 6th. Argus lifted their price objective on Axon Enterprise from $460.00 to $600.00 and gave the company a “buy” rating in a research report on Thursday, September 3rd. Weiss Ratings reiterated a “hold (c-)” rating on shares of Axon Enterprise in a research note on Tuesday. Finally, Royal Bank Of Canada reduced their target price on shares of Axon Enterprise from $735.00 to $615.00 and set an “outperform” rating for the company in a report on Friday. Thirteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $631.35.

Insider Transactions at Axon Enterprise

In related news, insider Isaiah Fields sold 1,017 shares of the business’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $480.45, for a total value of $488,617.65. Following the sale, the insider directly owned 56,264 shares in the company, valued at approximately $27,032,038.80. The trade was a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jeffrey C. Kunins sold 9,605 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $626.70, for a total value of $6,019,453.50. Following the transaction, the insider directly owned 97,761 shares of the company’s stock, valued at approximately $61,266,818.70. The trade was a 8.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 37,397 shares of company stock worth $21,234,034. 4.20% of the stock is currently owned by company insiders.

More Axon Enterprise News

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q3 revenue reached a record $909 million, up 28% year over year, while software and services revenue rose 43%. Axon also reported AI annual recurring revenue above $100 million, signaling continued demand for its software and AI offerings. Axon Q3 results
• Neutral Sentiment: Axon committed an additional $1.2 billion to drone maker Skydio, bringing its stake to 37% and making it Skydio’s exclusive public-safety distributor in the U.S. and Canada. The move could expand Axon’s Drone as First Responder business, but its scale also raises investment and execution risks. Reuters: Axon invests in Skydio
• Negative Sentiment: Q3 adjusted earnings of $1.72 per share and revenue of $908.55 million fell short of analyst expectations. Axon’s 2026 revenue forecast was reduced to $3.6 billion from a consensus of about $3.7 billion; its Q4 revenue guidance also came in below estimates. The company cited delays in federal counter-drone projects, while margin pressure added to concerns. Zacks: Q3 miss and outlook
• Negative Sentiment: Several analysts lowered price targets after the results, and Craig Hallum downgraded AXON from Buy to Hold, adding to pressure on investor sentiment. Benzinga: analyst forecast changes
• Negative Sentiment: A class-action lawsuit over Axon’s license-plate surveillance practices is a potential additional legal and reputational overhang. Class-action announcement

Axon Enterprise Price Performance

AXON traded down $69.56 during trading on Friday, reaching $313.00. 5,224,684 shares of the company traded hands, compared to its average volume of 975,165. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.80 and a current ratio of 2.15. Axon Enterprise, Inc has a 12-month low of $307.00 and a 12-month high of $665.07. The firm has a fifty day simple moving average of $441.53 and a 200 day simple moving average of $475.20. The company has a market cap of $25.43 billion, a P/E ratio of 100.32, a PEG ratio of 8.09 and a beta of 1.48.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Thursday, November 5th. The biotechnology company reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.89 by ($0.17). The company had revenue of $908.55 million for the quarter, compared to the consensus estimate of $934.33 million. Axon Enterprise had a return on equity of 2.84% and a net margin of 6.19%. Axon Enterprise’s revenue was up 27.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.17 EPS. On average, equities analysts forecast that Axon Enterprise, Inc will post 2.10 EPS for the current year.

Axon Enterprise Profile

Axon Enterprise develops technology and services for public safety agencies. Its products include TASER conducted-energy weapons, body-worn and in-car cameras, and related hardware designed to support law enforcement and other safety professionals.

The company also provides cloud-based software for managing digital evidence, records and operational workflows. Its Axon Evidence platform helps agencies store, organize and share video and other evidence, while its broader software offerings include tools for dispatch and records management.

Founded in 1993 as TASER International, the company adopted the name Axon Enterprise in 2017 as it expanded beyond conducted-energy weapons into connected devices and software.